Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This trial is to
evaluate the efficacy and safety of apatinib mesylate combined with doxorubicin and
ifosfamide in the treatment of advanced soft tissue sarcoma.